Research Insights
Insights are moderated by the Research Hub team and offer an at-a-glance overview of interesting research findings.
Combined Ma Huang Fu Zi Xi Xin decoction and Shen Mai injection treatment showed improved heart rate and symptoms in under 60s with bradyarrhythmia
Systematic Review Bradyarrythmia Fu Zi Ma Huang
Using Ma Huang Fu Zi Xi Xin decoction along with Shen Mai injection (SMI) treatment is better than just SMI treatment for patients under 60 with bradyarrhythmia. This combo improves heart rate and reduces symptoms, with no major side effects. The combination's effectiveness might come from shared heart-rate boosting components. However, there were differences in heart rate data due to varied ECG analysis.
View Article
HuoXiang ZhengQi (HQXXD) may be a safe and effective treatment for Chronic Cough Variant Asthma (CVA), improving clinical efficacy and airway responsiveness while reducing recurrence rates.
Systematic Review Asthma Cough Huang Qi
HuoXiang ZhengQi (HQXXD) for Chronic Cough Variant Asthma (CVA) was systematically evaluated. The HQXXD group showed significantly higher total effective rates of clinical efficacy and airway responsiveness compared to the control group, while the recurrence rate was lower. Adverse reactions were not reported in HQXXD treatment, indicating its safety for CVA patients.
View Article
Asthma severity can be notably reduced by Xi Xin essential oil, which decreases inflammation, immunoglobulins, and fibrotic mediators, while also alleviating airway obstruction.
Network Pharmacology Asthma
AEO was administered via a nebulizer for three weeks ahead of exposing mice to ovalbumin (OVA), a protein commonly used to provoke an allergic reaction, and particulate matter (PM), common air pollutants. Co-treatment of AEO, OVA, and PM was carried out for four weeks. Additionally, A549 lung epithelial cells were exposed to PM to study the influence of AEO on lung-fibrosis-related factors.
In our study, we found that AEO notably inhibited goblet cell accumulation, which led to a decrease in epithelial thickness. Collagen deposition in lung tissues, a common marker of airway remodeling, was significantly inhibited by AEO in asthmatic mice exposed to OVA and PM. AEO also lessened the influx of inflammatory cells into the bronchoalveolar lavage fluid, an indicator of respiratory inflammation. Similarly, the increases in serum IgE and IgG, immunoglobulins associated with allergic reactions, and cytokines in lung tissues were reduced by AEO. Moreover, AEO successfully managed the expression of key fibrotic mediators, particularly POSTN and TGF-β. All these indicators point to AEO's potential as a promising therapeutic treatment to alleviate asthma symptoms.
View Article
Clinical Trials
Clinical trials are research studies that involve people and are conducted to evaluate the safety and efficacy of new treatments or interventions, such as drugs, medical devices, or behavioural therapies.
Study Protocols
Published study protocols are detailed plans that outline the objectives, methodology, statistical analyses, and organisation of a research study that have been made publicly available for others to review and use as a reference.
Presentation Slides
Chinese Medicine Research Hub
Systematic Review
Combined Ma Huang Fu Zi Xi Xin decoction and Shen Mai injection treatment showed improved heart rate and symptoms in under 60s with bradyarrhythmia
2023 Evidence-Based Complementary and Alternative Medicine Efficacy Evaluation of the Mahuang-Fuzi-Xixin Decoction in Combination with Shenmai Injection for Bradyarrhythmia Treatment: A Systematic Review and Meta-Analysis
Zhang Z, Li Y, Yu T, Yan M, Li S
Chinese Medicine Research Hub
Systematic Review
HuoXiang ZhengQi (HQXXD) may be a safe and effective treatment for Chronic Cough Variant Asthma (CVA), improving clinical efficacy and airway responsiveness while reducing recurrence rates.
2022 Evidence-Based Complementary and Alternative Medicine The Effectiveness and Safety of Huangqi Xixin Decoction for Cough Variant Asthma: A Systematic Review and Meta-Analysis
Wang C, Xia Q, Hu B, Jiang W, Zhang H
Chinese Medicine Research Hub
Network Pharmacology
Asthma severity can be notably reduced by Xi Xin essential oil, which decreases inflammation, immunoglobulins, and fibrotic mediators, while also alleviating airway obstruction.
2022 Pharmaceutics Exploring the Potential Effects and Mechanisms of Asarum sieboldii Radix Essential Oil for Treatment of Asthma
Han JM, Kim MH, Choi LY, Kim G, Yang WM
Executive Summary
Write an executive summary in the form of a blog article on the topic of "Research into Chinese medicine treatment for Xi Xin" summarising the research below and using language that can be easily understood by patients and avoiding medical jargon using a professional and caring tone of voice.
Write an executive summary in the form of a blog article on the topic of "Researched Chinese medicine treatments for Xi Xin" summarising the research below in an objective and easy to understand way, and using language that can be easily understood by patients. Group the article into Chinese medicine treatments first, followed by nutrition and other treatments. Avoid using medical jargon and use a professional and caring tone of voice.
Write me a concise but easy to understand executive summary on the topic of "Chinese medicine treatments for Xi Xin" based on the following research that I will give you. Your summary should be 2 paragraphs long in Australian English spelling and include references to the studies.
A Systematic Review published in 2023 in the journal Evidence-Based Complementary and Alternative Medicine found that Combined Ma Huang Fu Zi Xi Xin decoction and Shen Mai injection treatment showed improved heart rate and symptoms in under 60s with bradyarrhythmia Using Ma Huang Fu Zi Xi Xin decoction along with Shen Mai injection (SMI) treatment is better than just SMI treatment for patients under 60 with bradyarrhythmia. This combo improves heart rate and reduces symptoms, with no major side effects. The combination's effectiveness might come from shared heart-rate boosting components. However, there were differences in heart rate data due to varied ECG analysis.
A Systematic Review published in 2022 in the journal Evidence-Based Complementary and Alternative Medicine found that HuoXiang ZhengQi (HQXXD) may be a safe and effective treatment for Chronic Cough Variant Asthma (CVA), improving clinical efficacy and airway responsiveness while reducing recurrence rates. HuoXiang ZhengQi (HQXXD) for Chronic Cough Variant Asthma (CVA) was systematically evaluated. The HQXXD group showed significantly higher total effective rates of clinical efficacy and airway responsiveness compared to the control group, while the recurrence rate was lower. Adverse reactions were not reported in HQXXD treatment, indicating its safety for CVA patients.
A Network Pharmacology published in 2022 in the journal Pharmaceutics found that Asthma severity can be notably reduced by Xi Xin essential oil, which decreases inflammation, immunoglobulins, and fibrotic mediators, while also alleviating airway obstruction. AEO was administered via a nebulizer for three weeks ahead of exposing mice to ovalbumin (OVA), a protein commonly used to provoke an allergic reaction, and particulate matter (PM), common air pollutants. Co-treatment of AEO, OVA, and PM was carried out for four weeks. Additionally, A549 lung epithelial cells were exposed to PM to study the influence of AEO on lung-fibrosis-related factors.
In our study, we found that AEO notably inhibited goblet cell accumulation, which led to a decrease in epithelial thickness. Collagen deposition in lung tissues, a common marker of airway remodeling, was significantly inhibited by AEO in asthmatic mice exposed to OVA and PM. AEO also lessened the influx of inflammatory cells into the bronchoalveolar lavage fluid, an indicator of respiratory inflammation. Similarly, the increases in serum IgE and IgG, immunoglobulins associated with allergic reactions, and cytokines in lung tissues were reduced by AEO. Moreover, AEO successfully managed the expression of key fibrotic mediators, particularly POSTN and TGF-β. All these indicators point to AEO's potential as a promising therapeutic treatment to alleviate asthma symptoms.
Can't find journal cover —Adrian Y 1 Mar 2023